Indications and uses
Helps prevent sunburn. If used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun.
Scott-Vincent Borba
- Manufacturer
- Scott-Vincent Borba
- Effective date
- 2012-06-20
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:32:29
Label at a glance#
ProductScott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29
Active ingredientZinc Oxide
Label structure11 sections
Dosage and administration
For sunscreen use: Apply liberally 15 minutes before sun exposure. Use a water resistant sunscreen if swimming or sweating. Reapply at least every 2 hours. Children under 6 months: Ask a doctor. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun prot...
Storage and handling
Protect this product from excessive heat and direct sun.
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
DRUG FACTS
ACTIVE INGREDIENTS
Zinc Oxide 18%
PURPOSE
Sunscreen
USES
- Helps prevent sunburn.
- If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun.
WARNINGS
For external use only.
OTC - DO NOT USE SECTION
Do not use on damaged or broken skin.
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs.
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rise with water to remove.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
DIRECTIONS
For sunscreen use:
- Apply liberally 15 minutes before sun exposure.
- Use a water resistant sunscreen if swimming or sweating.
- Reapply at least every 2 hours.
- Children under 6 months: Ask a doctor.
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including:
- Limit time in sun, especially from 10 a.m.-2 p.m.
- Wear long-sleeved shirts, pants, hats, and sunglasses.
INACTIVE INGREDIENTS
MICA, ZINC STEARATE, SILICA, LAUROYL LYSINE, SQUALANE, ETHYLHEXYL PALMITATE, OCTYLDODECYL STEAROYL STEARATE, ARGANIA SPINOSA KERNEL OIL, GLYCERYL CAPRYLATE, P-ANISIC ACID, TAPIOCA STARCH, POLYMETHYLSILSESQUIOXANE, DIAMOND POWDER, LONICERA CAPRIFOLIUM (HONEYSUCKLE) FLOWER EXTRACT, LONICERA JAPONICA (HONEYSUCKLE) FLOWER EXTRACT, SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL, TOCOPHEROL, RETINYL PALMITATE, HYALURONIC ACID, MYRCIARIA DUBIA FRUIT EXTRACT, CARTHAMUS TINCTORIUS (SAFFLOWER) SEED OIL, PRUNUS AVIUM (SWEET CHERRY) FRUIT EXTRACT, CUMINUM CYMINUM (CUMIN) SEED EXTRACT, ARNICA MONTANA FLOWER EXTRACT, LYCIUM BARBARUM FRUIT EXTRACT MAY CONTAIN: TITANIUM DIOXIDE (CI 77891),IRON OXIDES (CL 77491, CL 77492, CL 77499), BISMUTH OXYCHLORIDE (CI 77163).
OTHER INFORMATION
- Protect this product from excessive heat and direct sun.
QUESTIONS OR COMMENTS
Call toll free 1-800-698-6858
SPL UNCLASSIFIED SECTION
Dist. by Scott-Vincent Borba
Inc. Hollywood, CA 90068.
PRINCIPAL DISPLAY PANEL - 5.6 g Package Carton
SCOTT-VINCENT BORBA
Anti-Fatigue 8 Hour Mineral Foundation
Anti-Wrinkle Treatment Duo
with Broad Spectrum SPF 29
NET WT 0.20 OZ (5.6 g)
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 51625-001-01 | 2021-01-29 | C162847 | 48780-1 | 97449f38-d229-f6ea-e053-dbdaa90aa703 | Scott-Vincent Borba Anti-Fatigue 8 Hour Mineral Foundation with Broad Spectrum SPF 29 |
| 51625-002-01 | 2021-01-29 | C162847 | 48780-1 | 97449f38-d229-f6ea-e053-dbdaa90aa703 | Scott-Vincent Borba Anti-Fatigue 8 Hour Mineral Foundation with Broad Spectrum SPF 29 |
| 51625-003-01 | 2021-01-29 | C162847 | 48780-1 | 97449f38-d229-f6ea-e053-dbdaa90aa703 | Scott-Vincent Borba Anti-Fatigue 8 Hour Mineral Foundation with Broad Spectrum SPF 29 |
| 51625-001-01 | 2019-11-13 | C162847 | 48780-1 | 97449f38-d229-f6ea-e053-dbdaa90aa703 | Scott-Vincent Borba Anti-Fatigue 8 Hour Mineral Foundation with Broad Spectrum SPF 29 |
| 51625-002-01 | 2019-11-13 | C162847 | 48780-1 | 97449f38-d229-f6ea-e053-dbdaa90aa703 | Scott-Vincent Borba Anti-Fatigue 8 Hour Mineral Foundation with Broad Spectrum SPF 29 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51625-001-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 1 in 1 CARTON | POWDER | 1 | 1 | |
| 51625-001-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 5.6 g in 1 PACKAGE, COMBINATION | POWDER | 5.6 | 1 | |
| 51625-002-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 5.6 g in 1 PACKAGE, COMBINATION | POWDER | 5.6 | 1 | |
| 51625-002-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 1 in 1 CARTON | POWDER | 1 | 1 | |
| 51625-003-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 1 in 1 CARTON | POWDER | 1 | 1 | |
| 51625-003-01 | Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29 | 5.6 g in 1 PACKAGE, COMBINATION | POWDER | 5.6 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51625-001 | SCOTT-VINCENT BORBA ANTI-FATIGE 8 HOUR MINERAL FOUNDATION WITH BROAD SPECTRUM SPF 29 (ZINC OXIDE) POWDER [SCOTT-VINCENT BORBA] | 1 | Legacy NDC, 2 package rows | 20120705_aacbc5a1-ee13-4ea3-9f68-8fb06ac3d877.zip |
| 51625-002 | SCOTT-VINCENT BORBA ANTI-FATIGE 8 HOUR MINERAL FOUNDATION WITH BROAD SPECTRUM SPF 29 (ZINC OXIDE) POWDER [SCOTT-VINCENT BORBA] | 1 | Legacy NDC, 2 package rows | 20120705_aacbc5a1-ee13-4ea3-9f68-8fb06ac3d877.zip |
| 51625-003 | SCOTT-VINCENT BORBA ANTI-FATIGE 8 HOUR MINERAL FOUNDATION WITH BROAD SPECTRUM SPF 29 (ZINC OXIDE) POWDER [SCOTT-VINCENT BORBA] | 1 | Legacy NDC, 2 package rows | 20120705_aacbc5a1-ee13-4ea3-9f68-8fb06ac3d877.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| Zinc Oxide | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| ARGAN OIL | INACTIVE INGREDIENT | 4V59G5UW9X | 1 | |
| ARNICA MONTANA FLOWER | INACTIVE INGREDIENT | OZ0E5Y15PZ | 1 | |
| BISMUTH OXYCHLORIDE | INACTIVE INGREDIENT | 4ZR792I587 | 1 | |
| CUMIN | INACTIVE INGREDIENT | AG9BNA51DQ | 1 | |
| DIAMOND | INACTIVE INGREDIENT | 6GRV67N0U2 | 1 | |
| ETHYLHEXYL PALMITATE | INACTIVE INGREDIENT | 2865993309 | 1 | |
| GLYCERYL CAPRYLATE | INACTIVE INGREDIENT | TM2TZD4G4A | 1 | |
| HYALURONIC ACID | INACTIVE INGREDIENT | S270N0TRQY | 1 | |
| JOJOBA OIL | INACTIVE INGREDIENT | 724GKU717M | 1 | |
| LAUROYL LYSINE | INACTIVE INGREDIENT | 113171Q70B | 1 | |
| LONICERA CAPRIFOLIUM FLOWER | INACTIVE INGREDIENT | 5N1WD9784U | 1 | |
| LONICERA JAPONICA FLOWER | INACTIVE INGREDIENT | 4465L2WS4Y | 1 | |
| LYCIUM BARBARUM FRUIT | INACTIVE INGREDIENT | 930626MWDL | 1 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 1 | |
| MYRCIARIA DUBIA FRUIT | INACTIVE INGREDIENT | YSW4EM1EKP | 1 | |
| OCTYLDODECYL STEAROYL STEARATE | INACTIVE INGREDIENT | 3D47Q6D93C | 1 | |
| P-ANISIC ACID | INACTIVE INGREDIENT | 4SB6Y7DMM3 | 1 | |
| SAFFLOWER OIL | INACTIVE INGREDIENT | 65UEH262IS | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| SQUALANE | INACTIVE INGREDIENT | GW89575KF9 | 1 | |
| STARCH, TAPIOCA | INACTIVE INGREDIENT | 24SC3U704I | 1 | |
| SWEET CHERRY | INACTIVE INGREDIENT | 93T4562ZI3 | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| TOCOPHEROL | INACTIVE INGREDIENT | R0ZB2556P8 | 1 | |
| VITAMIN A PALMITATE | INACTIVE INGREDIENT | 1D1K0N0VVC | 1 | |
| ZINC STEARATE | INACTIVE INGREDIENT | H92E6QA4FV | 1 |
Products#
Every source-derived product name is available through these pages.
- Scott-Vincent Borba Anti-Fatige 8 Hour Mineral Foundation with Broad Spectrum SPF 29
- Zinc Oxide
- MICA
- ZINC STEARATE
- SILICON DIOXIDE
- LAUROYL LYSINE
- SQUALANE
- ETHYLHEXYL PALMITATE
- OCTYLDODECYL STEAROYL STEARATE
- ARGAN OIL
- GLYCERYL CAPRYLATE
- P-ANISIC ACID
- STARCH, TAPIOCA
- DIAMOND
- LONICERA CAPRIFOLIUM FLOWER
- LONICERA JAPONICA FLOWER
- JOJOBA OIL
- TOCOPHEROL
- VITAMIN A PALMITATE
- HYALURONIC ACID
- MYRCIARIA DUBIA FRUIT
- SAFFLOWER OIL
- SWEET CHERRY
- CUMIN
- ARNICA MONTANA FLOWER
- LYCIUM BARBARUM FRUIT
- TITANIUM DIOXIDE
- BISMUTH OXYCHLORIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 51625-001 | 51625-001-01 |
| 51625-002 | 51625-002-01 |
| 51625-003 | 51625-003-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, LIQUID FILLED / ORAL | 12 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / ORAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| SQUALANE | SQUALANE | GW89575KF9 | CREAM, AUGMENTED / TOPICAL | 120 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED / ORAL | 17 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | SHAMPOO / TOPICAL | 2 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| TOCOPHEROL | TOCOPHEROL | R0ZB2556P8 | INJECTION, EMULSION / INTRAVENOUS | 0.02 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| GLYCERYL CAPRYLATE | GLYCERYL MONOCAPRYLATE | TM2TZD4G4A | CAPSULE / ORAL | 400 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | OINTMENT / TOPICAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| SQUALANE | SQUALANE | GW89575KF9 | SOLUTION / TOPICAL | 1 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | TABLET, EXTENDED RELEASE / ORAL | 36 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM / BUCCAL | 3 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SOLUTION / ORAL | 1.8 mg/120ml | ||
| TOCOPHEROL | TOCOPHEROL | R0ZB2556P8 | TABLET / ORAL | 0.08 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | TABLET, COATED / ORAL | 1.82 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| STARCH, TAPIOCA | STARCH, TAPIOCA | 24SC3U704I | CAPSULE / ORAL | 100 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | TABLET / ORAL | 72 mg | ||
| SQUALANE | SQUALANE | GW89575KF9 | AEROSOL, FOAM / TOPICAL | 2.23 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| GLYCERYL CAPRYLATE | GLYCERYL MONOCAPRYLATE | TM2TZD4G4A | TABLET / ORAL | 1 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| TOCOPHEROL | TOCOPHEROL | R0ZB2556P8 | CREAM / TOPICAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 11 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | CAPSULE / ORAL | 2.04 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 85ebeb0a-32e1-4d7e-a628-e6980f8a86e4 | aacbc5a1-ee13-4ea3-9f68-8fb06ac3d877 | 2012-06-20 | Warnings | 85ebeb0a-32e1-4d7e-a628-e6980f8a86e4 aacbc5a1-ee13-4ea3-9f68-8fb06ac3d877 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.